Briefing
Blinatumomab for MRD-Negative Acute Lymphoblastic Leukemia in Adults (E1910)
Phase 3 trial in adults 30-70 years with BCR::ABL1-negative BCP-ALL who had MRD-negative remission after induction/intensification. 224 MRD-negative patients were randomized 1:1 to 4 cycles of blinatumomab plus consolidation chemotherapy vs chemotherapy alone. At median follow-up 43 months, 3-year OS was 85% vs 68% (HR for death 0.41, 95% CI 0.23-0.73, P=0.002); 3-year RFS 80% vs 64% (HR 0.53, 95% CI 0.32-0.87). Level 1 (randomized, MRD-defined eligibility).
- Design: paper
- n: 224
- Assay: Flow-cytometry MRD; MRD-negative defined as <0.01% leukemic cells in bone marrow